Tofajak-In 5mg

Tofajak-In 5mg tablet contains tofacitinib as its active ingredient. This medication is classified as a disease-modifying anti-rheumatic drug (DMARD) and falls under the category of immunomodulators. It is prescribed either alone or in combination with other treatments for adults suffering from rheumatoid arthritis, a condition where the body attacks its joints, leading to pain, swelling, and functional impairment, particularly in those who cannot tolerate or do not respond to alternative therapies. Additionally, it is utilized for managing psoriatic arthritis, which results in joint pain and swelling, along with skin scaling. Furthermore, it is indicated for adult patients experiencing moderately to severely active ulcerative colitis.

The tofajak-In 5mg tablet also has applications in treating ankylosing spondylitis, an inflammatory condition affecting the spine. It is effective for active polyarticular juvenile idiopathic arthritis, a chronic illness primarily causing joint pain and swelling in patients aged 2 years and older. The mechanism of action involves reducing immune system activity. It is crucial to inform your physician if you have a severe blood infection, active tuberculosis, or liver issues. Additionally, notify your doctor if you have a history of hepatitis B infection, as this medication may reactivate the virus.

Avoid using tofajak-In 5mg tablet if you are allergic to tofacitinib or any of its components. It is important to inform your healthcare provider if you exhibit any signs of infection, such as fever, sweating, chills, muscle pain, cough, shortness of breath, weight loss, skin lesions, difficulty or pain while swallowing, diarrhea, or abdominal discomfort. Prior to starting treatment, discuss with your physician if you have kidney, heart, lung, or liver conditions, a history of tuberculosis, high blood pressure, or high cholesterol, and whether you are a current or former smoker.